6L70 image
Deposition Date 2019-10-30
Release Date 2020-04-29
Last Version Date 2024-11-13
Entry Detail
PDB ID:
6L70
Keywords:
Title:
Complex structure of PEDV 3CLpro with GC376
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.56 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:PEDV main protease
Gene (Uniprot):Pol1
Chain IDs:A, B
Chain Length:305
Number of Molecules:2
Biological Source:Porcine epidemic diarrhea virus
Ligand Molecules
Primary Citation
Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376.
Viruses 12 ? ? (2020)
PMID: 32098094 DOI: 10.3390/v12020240

Abstact

Porcine epidemic diarrhea virus (PEDV), being highly virulent and contagious in piglets, has caused significant damage to the pork industries of many countries worldwide. There are no commercial drugs targeting coronaviruses (CoVs), and few studies on anti-PEDV inhibitors. The coronavirus 3C-like protease (3CLpro) has a conserved structure and catalytic mechanism and plays a key role during viral polyprotein processing, thus serving as an appealing antiviral drug target. Here, we report the anti-PEDV effect of the broad-spectrum inhibitor GC376 (targeting 3Cpro or 3CLpro of viruses in the picornavirus-like supercluster). GC376 was highly effective against the PEDV 3CLpro and exerted similar inhibitory effects on two PEDV strains. Furthermore, the structure of the PEDV 3CLpro in complex with GC376 was determined at 1.65 Å. We elucidated structural details and analyzed the differences between GC376 binding with the PEDV 3CLpro and GC376 binding with the transmissible gastroenteritis virus (TGEV) 3CLpro. Finally, we explored the substrate specificity of PEDV 3CLpro at the P2 site and analyzed the effects of Leu group modification in GC376 on inhibiting PEDV infection. This study helps us to understand better the PEDV 3CLpro substrate specificity, providing information on the optimization of GC376 for development as an antiviral therapeutic against coronaviruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures